Floatz Rating
B57/100
Confidence
Indicative
Sponsor
University Health Network, Toronto
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03991832CT.gov Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors | — | Recruiting | — | — | — |
NCT03212274CT.gov Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations | — | Active Not Recruiting | — | — | — |
NCT03233204CT.gov Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | — | Completed | — | — | — |
NCT03155620CT.gov Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Glioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Olaparib (this asset) | University Health Network, Toronto | P2 | B · 57 |
| Olutasidenib | Rigel Pharmaceuticals | P4 | BBB |
| Irinotecan | Kailin Yang, MD, PhD | P3 | B |
| Dianhydrogalactitol | Kintara Therapeutics, Inc. | P2 | B |
| Valproic Acid | Medical University of South Carolina | P2 | B |
| Cyclophosphamide | Essen Biotech | P2 | B |
| Camustine | University of California, Davis | P3 | B |
| Nivolumab | Jason J. Luke, MD | P2 | B |
| Carboplatin | DelMar Pharmaceuticals, Inc. | P3 | B |
+42 more in the Glioma cohort
Other indications for Olaparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 73 |
| Fallopian Tube Serous Adenocarcinoma | — | P3 | BBB · 72 |
| Ovarian Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Olaparib in Glioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/olaparib-glioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →